OBJECTIVE: To investigate the efficacy of @entity500 in treating @entity1 with severe @entity31 . DESIGN: One-year, randomized, placebo-controlled trial. SUBJECTS: 83 @entity1 with severe @entity31 were enrolled. Fifty @entity1 who relapsed within two months on @entity228 withdrawal were randomized into two groups. The @entity500 group received oral @entity3378 (6-8 g/day), oral @entity617 (1 mg/Kg/day) and oral @entity500 (2 mg/Kg/day). The placebo group received oral @entity3378 (6-8 g/day), oral @entity617 (1 mg/Kg/day) and placebo. Corticosteroids were tapered over 12-16 weeks. RESULTS: Five @entity1 (2 in @entity500 group, 3 in placebo group) dropped out of the study. Three @entity1 in the @entity500 group had side effects. The number of @entity1 going into complete remission and partial remission was not significantly different in the two groups. The proportion of relapses in the @entity500 group was lower than in the placebo group (p < 0.05). CONCLUSIONS: In @entity1 with @entity31 , @entity500 had no effect in achieving remission, when given in combination with @entity617 ; however, it lowers the proportion of relapses. Side effects like @entity788 and @entity99 are mild and respond promptly to drug withdrawal.

Role of @entity500 in severe XXXX : one-year, placebo-controlled, randomized trial.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis'] @entity500 :: ('MESH:D001379', 'Chemical') :: ['azathioprine'] @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis'] @entity228 :: ('CHEBI:50858', 'Chemical') :: ['corticosteroid'] @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatitis'] @entity3378 :: ('MESH:D012460', 'Chemical') :: ['sulfasalazine'] @entity617 :: ('MESH:D011239', 'Chemical') :: ['prednisolone']
@entity31 :: (MESH:D003093,Disease) :: ['ulcerative colitis']
